CMAJ • May 9, 2006; 174 (10). doi:10.1503/cmaj.051700.
© 2006 CMA Media Inc. or its licensors
All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association.
This Article
Right arrow Abstract
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dib, N.
Right arrow Articles by Calès, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dib, N.
Right arrow Articles by Calès, P.
Related Collections
Right arrow Liver (including hepatitis and cirrhosis)

Current management of the complications of portal hypertension: variceal bleeding and ascites

Nina Dib, Frédéric Oberti and Paul Calès

From the Department of Hepato-Gastroenterology, University Hospital, and HIFIH Laboratory, Université d'Angers, Angers, France (all authors).


Figure 118
View larger version (59K):

[in a new window]
  		Fig. 1: Pathophysiology of portal hypertension in cirrhosis. Portal hypertension results from increased intrahepatic vascular resistance and portal–splanchnic blood flow. In addition, cirrhosis is characterized by splanchnic and systemic arterial vasodilation. Splanchnic arterial vasodilation leads to increased portal blood flow and thus elevated portal hypertension. An increased hepatic venous pressure gradient leads to the formation of portosystemic venous collaterals. Esophagogastric varices represent the most clinically important collaterals given their associated high risk of bleeding. Treatment consists of pharmacologic therapy to decrease portal pressure, endoscopic treatment of varices (band ligation or sclerotherapy) to treat variceal bleeding, and creation of a transjugular intrahepatic portosystemic shunt (TIPS) to reduce portal pressure if drug therapy and endoscopic treatment fail. Photo by: Lianne Friesen and Nicholas Woolridge

 

Figure 118
View larger version (126K):

[in a new window]
  		Box 1.

 

Figure 218
View larger version (30K):

[in a new window]
  		Fig. 2: Algorithm for the treatment of variceal bleeding. TIPS = transjugular intrahepatic portosystemic shunt. *The therapeutic option depends on what was done in primary prophylaxis.

 

Figure 318
View larger version (29K):

[in a new window]
  		Fig. 3: Prophylaxis of variceal bleeding in cirrhosis. Preprimary prophylaxis is aimed at preventing esophagogastric varices (EV) from developing. The goal of primary prophylaxis is to prevent a first variceal bleeding episode once medium or large varices have formed. Secondary prophylaxis is used to prevent recurrent variceal bleeding. Photo by: Lianne Friesen and Nicholas Woolridge

 

Figure 218
View larger version (71K):

[in a new window]
  		Box 2.

 

Figure 418
View larger version (23K):

[in a new window]
  		Fig. 4: Algorithm for the primary prophylaxis of variceal bleeding in cirrhosis.

 

Figure 318
View larger version (114K):

[in a new window]
  		Box 3.

 

View this table:

[in a new window]
  		Appendix 1.